Figure 3
Survival of patients with triple-negative breast cancer based on E-cadherin and Ki67 expression. (A) TNBC with reduced E-cadherin expression showed a significantly worse overall survival time (P = 0.0054), and cases with Ki67 expression showed significantly worse overall survival time (P = 0.0181). Patients with E-cadherin-negative and Ki67-positive expression showed a significantly worse overall survival time (P = 0.001). (B) The prognosis of the E-cadherin-negative cancer patients was significantly poorer than that of the E-cadherin-positive cancer patients in regard to overall survival (P = 0.0058) in Stage II. The prognosis of the combination of E-cadherin-negative and Ki67-positive expression cancer patients was significantly poorer than that of the combination of E-cadherin-positive and Ki67-negative expression cancer patients in regard to overall survival and in Stage II (P = 0.0376).